Appendix: Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment

dataset

posted on 2024-02-05, 12:41 authored by Daniel Aggio, Katy Gallop, Villum Wittrup-Jensen, Soulmaz Farsani, Andrew Lloyd

These are peer-reviewed supplementary appendices and figures for the article 'Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment' published in the Journal of Comparative Effectiveness Research.

Appendix file 1: General Public DCE Survey
Appendix file 2: Sample DCE choice questions
Appendix File 3: Estimated marginal utilities among NASH patients by fibrosis stage based on results from conditional logit model
Appendix File 4: NASH Check scores and frequency of symptoms by NASH Fibrosis Stage
Appendix File 5: Linear regression results exploring associations between background and clinical characteristics with EQ-5D utility values in the patient sample (n=154)

Background: This study estimated utility values for non-alcoholic steatohepatitis (NASH). Previous studies have assumed that health-related quality of life does not vary between the early stages of NASH. Materials & Methods: Discrete choice experiment (DCE) surveys estimated the value of avoiding fibrosis progression. Patients also completed the EQ-5D-5L. Marginal rates of substitution estimated utility change associated with fibrosis progression. Results: DCE surveys were completed by the UK general public (n = 520) and patients with NASH (n = 154). The utility decline between fibrosis stages F1 and F4 decompensated was between -0.521 to -0.646 (depending on method). Conclusion: Three methods were used to estimate utilities for NASH, each one showed sensitivity to advancing fibrosis, including in the early stages, which is often considered asymptomatic.